Mendus – equity proposition

Mendus is a clinical stage immuno-oncology company based in Sweden and the Netherlands. It is focused on developing active immunotherapies that aim to improve long-term outcomes for patients with cancer, particularly in myeloid blood cancers where there remains significant unmet need. Its lead candidate, vididencel, is an off-the-shelf cellular immunotherapy designed to stimulate the patient’s own immune system against residual cancer cells. Mendus is developing vididencel across a broader acute myeloid leukaemia (AML) opportunity, covering both chemo-eligible and chemo-ineligible patient settings, while also expanding into chronic myeloid leukaemia (CML), where the goal is to support treatment-free remission.

We highlight four key reasons why Mendus may be considered a compelling investment opportunity.

1. Vididencel is supported by encouraging long-term clinical data in AML.
2. Mendus’s clinical development strategy significantly broadens the AML opportunity
3. Expansion into CML provides a new and potentially sizeable opportunity.
4. Multiple upcoming clinical catalysts may shape the next stage of development.

For more information on Mendus, please see our latest research.